UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology, a company focused on developing therapeutics for age-related diseases, has announced the granting of a stock-based award to its new chief strategy officer. The award, approved by the Compensation Committee of the Board of Directors, includes options to purchase 100,000 shares of UNITY common stock and 15,000 Restricted Stock Units. This grant, totaling 115,000 shares, was made under the UNITY 2020 Employment Inducement Incentive Plan, which was established to provide incentives for newly hired employees in accordance with Nasdaq Stock Market Rule 5635(c)(4). The award became effective on July 22, 2024, serving as a material inducement for the new executive to join UNITY.
UNITY Biotechnology, un'azienda focalizzata nello sviluppo di terapie per malattie legate all'età, ha annunciato l'assegnazione di un premio basato su azioni al suo nuovo chief strategy officer. Il premio, approvato dal Comitato per la Compensazione del Consiglio di Amministrazione, include opzioni per acquistare 100.000 azioni ordinarie di UNITY e 15.000 Unità di Azioni Riservate. Questa concessione, per un totale di 115.000 azioni, è stata effettuata nell'ambito del Piano di Induzione Occupazionale UNITY 2020, istituito per fornire incentivi ai dipendenti neoassunti in conformità con la Regola 5635(c)(4) del Nasdaq Stock Market. Il premio è entrato in vigore il 22 luglio 2024, fungendo da incentivo materiale per il nuovo dirigente a unirsi a UNITY.
UNITY Biotechnology, una empresa centrada en el desarrollo de terapias para enfermedades relacionadas con la edad, ha anunciado la concesión de un premio basado en acciones a su nuevo director de estrategia. El premio, aprobado por el Comité de Compensación de la Junta Directiva, incluye opciones para adquirir 100.000 acciones ordinarias de UNITY y 15.000 Unidades de Acciones Restringidas. Esta concesión, que suma un total de 115.000 acciones, se realizó bajo el Plan de Incentivos por Inducción Laboral UNITY 2020, establecido para proporcionar incentivos a los empleados recién contratados según la Regla 5635(c)(4) del Mercado de Valores Nasdaq. El premio entró en vigor el 22 de julio de 2024, sirviendo como un incentivo material para que el nuevo ejecutivo se uniera a UNITY.
UNITY Biotechnology는 노인성 질병 치료제를 개발하는 회사로, 새로운 전략 담당 이사에게 주식 기반 보상을 지급한다고 발표했습니다. 이 보상은 이사회 보상위원회의 승인을 받았으며, UNITY 보통주 100,000주 매수 옵션과 15,000주 제한주식단위를 포함합니다. 총 115,000주에 해당하는 이 보상은 UNITY 2020 고용 유인 인센티브 계획의 일환으로 이루어진 것으로, 이는 Nasdaq 주식 시장 규칙 5635(c)(4)에 따라 새로 고용된 직원들에게 인센티브를 제공하기 위해 설립되었습니다. 이 보상은 2024년 7월 22일에 발효되어 새로운 경영진이 UNITY에 합류하도록 유도하는 중요한 역할을 했습니다.
UNITY Biotechnology, une entreprise axée sur le développement de traitements pour les maladies liées à l'âge, a annoncé l'octroi d'une récompense en actions à son nouveau directeur de la stratégie. La récompense, approuvée par le Comité de Compensation du Conseil d'Administration, comprend des options pour acheter 100 000 actions ordinaires d'UNITY et 15 000 unités d'actions restreintes. Ce don, totalisant 115 000 actions, a été effectué dans le cadre du Plan d'Incitation à l'Emploi UNITY 2020, qui a été établi pour fournir des incitations aux employés nouvellement embauchés conformément à la Règle 5635(c)(4) du marché boursier Nasdaq. La récompense est entrée en vigueur le 22 juillet 2024, servant de motivation matérielle pour que le nouveau dirigeant rejoigne UNITY.
UNITY Biotechnology, ein Unternehmen, das sich auf die Entwicklung von Therapien für altersbedingte Krankheiten konzentriert, hat die Gewährung eines aktienbasierten Preises an seinen neuen Chief Strategy Officer bekannt gegeben. Die Auszeichnung, die vom Vergütungsausschuss des Vorstands genehmigt wurde, umfasst Optionen zum Kauf von 100.000 Aktien von UNITY und 15.000 Restricted Stock Units. Diese Vergabe, die insgesamt 115.000 Aktien beträgt, wurde im Rahmen des UNITY 2020 Employment Inducement Incentive Plans gewährt, der eingerichtet wurde, um Anreize für neu eingestellte Mitarbeiter gemäß der Regel 5635(c)(4) des Nasdaq-Aktienmarktes zu schaffen. Die Auszeichnung trat am 22. Juli 2024 in Kraft und diente als wesentlicher Anreiz für den neuen Geschäftsführer, zu UNITY zu stoßen.
- Appointment of a new chief strategy officer, potentially bringing fresh strategic insights
- Implementation of employee incentive plan to attract top talent
- Potential dilution of existing shareholders due to the issuance of new stock options and RSUs
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Compensation Committee of the Board of Directors (the “Board”) granted a stock-based award to a new employee, the company’s chief strategy officer, effective as of July 22, 2024, covering an aggregate of 115,000 shares of UNITY common stock, including options to purchase an aggregate of 100,000 shares of UNITY common stock and 15,000 Restricted Stock Units of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
What stock-based award did UNITY Biotechnology (UBX) grant to its new chief strategy officer?
Under which plan was the stock-based award granted by UNITY Biotechnology (UBX)?
What is the purpose of UNITY Biotechnology's (UBX) stock-based award to the new chief strategy officer?
When did UNITY Biotechnology (UBX) grant the stock-based award to its new chief strategy officer?
